Welcome to our dedicated page for Envoy Medical SEC filings (Ticker: COCH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Envoy Medical, Inc. (NASDAQ: COCH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as a hearing health business focused on fully implanted hearing devices. Envoy Medical files reports and registration statements that describe its Esteem® fully implanted active middle ear implant (FI-AMEI), the investigational fully implanted Acclaim® cochlear implant, its financial condition, capital structure, and key risks.
Through its Forms 10-Q and 10-K, Envoy Medical presents detailed financial statements and management discussion of operations, including net revenues from the Esteem FI-AMEI and related components, research and development expenses tied to the Acclaim pivotal clinical trial, and general and administrative costs associated with operating as a public company. These periodic reports also discuss liquidity, capital resources, and risk factors relevant to investors evaluating COCH.
Current reports on Form 8-K capture material events such as FDA approval to expand the pivotal clinical trial for the fully implanted Acclaim cochlear implant to its final stage, notices and determinations related to Nasdaq listing requirements, equity and warrant financing transactions, and quarterly earnings announcements. Proxy materials on Schedule 14A outline shareholder proposals, including approvals related to warrant issuances under Nasdaq rules, and provide additional context on the company’s capital raising activities.
Envoy Medical has also filed registration statements on Form S-1 and Form S-3 covering offerings of Class A common stock, pre-funded warrants, and the resale of shares underlying private placement warrants. These documents describe the company as an emerging growth company and a smaller reporting company, and they summarize its business focus on fully implanted hearing technologies, including the Esteem FI-AMEI and the investigational Acclaim cochlear implant.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, such as key changes in revenues and expenses, updates on the Acclaim clinical trial, new financing arrangements, and material listing or regulatory developments. Users can quickly review Forms 10-K and 10-Q for an overview of Envoy Medical’s financial performance, scan 8-K filings for significant events, and examine registration statements and proxy materials for details on securities offerings and shareholder approvals, all with real-time updates from the SEC’s EDGAR system.
BRYNELSEN CHARLES reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 2,600,000 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 600,000 shares.
Lucas Brent T. reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 162,500 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 37,500 shares.
TAYLOR GLEN A reported open-market purchase transactions in a Form 4 filing for COCH. The filing lists transactions totaling 48,750,000 shares at a weighted average price of $0.40 per share. Following the reported transactions, holdings were 11,250,000 shares.
Envoy Medical stockholder Glen A. Taylor filed an amended Schedule 13D to update his ownership after a February 2026 investment. He purchased 18,750,000 shares of Class A Common Stock together with Series A-1 Warrants for 11,250,000 shares and Series A-2 Warrants for 18,750,000 shares at a combined price of $0.40 per share and accompanying warrants, for an aggregate $7,500,000 funded with personal funds.
The common warrants have a $0.40 exercise price and become exercisable after stockholder approval of the warrant share issuance, with Series A-1 Warrants expiring up to 24 months after that approval (or earlier upon Milestone 1) and Series A-2 Warrants up to 60 months (or earlier upon Milestone 2). As of February 12, 2025, he is treated as beneficially owning 68,909,614 shares of Class A Common Stock, or 84.8% of the class, based on 76,881,110 shares outstanding immediately following the company’s offering, including the warrant shares. On the same date, he directly holds 29,040,049 outstanding shares, or 37.7% of those outstanding shares.
Envoy Medical, Inc. completed an upsized public offering that raised approximately $30.0 million in gross proceeds by selling an aggregate of 75,000,000 shares of Class A common stock (or pre-funded warrants in lieu) plus milestone-linked Series A-1 and Series A-2 warrants to purchase up to 120,000,000 additional shares.
The warrants carry a $0.40 exercise price and become exercisable after stockholder approval, with earlier expirations tied to FDA milestones for the company’s Acclaim cochlear implant. If fully exercised for cash, the warrants could bring in about $48.0 million more. Envoy plans to use the net proceeds for working capital and to fund its pivotal FDA clinical study, and it expects the financing to extend its cash runway into the second half of 2027.
Envoy Medical is registering up to 150,803,850 shares of Class A common stock underlying pre-funded, Series A-1, Series A-2 and placement agent warrants, alongside 47,946,150 shares of common stock and 27,053,850 pre-funded warrants sold in a best-efforts public offering at $0.40 per share and accompanying warrants. The deal implies a maximum gross raise of about $30.0 million and estimated net proceeds of roughly $27.8 million before any warrant exercises. There is no minimum offering amount, and H.C. Wainwright is acting as exclusive placement agent.
Common stock outstanding would rise from 28,934,960 to 103,934,960 shares if all pre-funded warrants are exercised and none of the new common or placement agent warrants are exercised. Company insiders are committing about $8.4 million of the raise. Envoy remains a loss-making, emerging growth medical device company, advancing its fully implanted Acclaim cochlear implant through a pivotal trial while facing Nasdaq listing compliance pressures and substantial ongoing capital needs.
Envoy Medical, Inc. is registering up to 150,803,850 shares of Class A common stock issuable from pre-funded, Series A-1, Series A-2 and placement agent warrants, alongside 47,946,150 new shares in a primary offering of stock and warrants at $0.40 per share and accompanying warrants.
The company expects gross proceeds of about $30.0 million and estimated net proceeds of roughly $27.8 million, with no minimum offering requirement in this reasonable best-efforts deal led by H.C. Wainwright. Company insiders plan to buy about 21.0 million shares plus warrants for approximately $8.4 million. Shares outstanding are expected to rise from 28,934,960 to 103,934,960, assuming all pre-funded warrants are exercised and no additional warrants are exercised.
Envoy is a hearing-health company developing the fully implanted Acclaim cochlear implant, now in the final stage of a pivotal U.S. trial, and has never been profitable. It reported net losses of $17.2 million for the nine months ended September 30, 2025 and carries a going-concern warning. The company also faces Nasdaq compliance pressures related to market value and minimum bid price listing standards.
Envoy Medical, Inc. reported that its Compensation Committee approved new stock option grants for its Chief Executive Officer and Interim Chief Financial Officer under the company’s 2023 Equity Incentive Plan.
On February 5, 2026, CEO Brent Lucas received options to purchase 200,000 shares of Class A common stock, and Interim CFO Robert Potashnick received options for 15,000 shares. Both grants have an exercise price of $0.53 per share, matching the closing price on the Nasdaq Capital Market on the award date. Twenty‑five percent of each grant vests after one year, with the remaining options vesting pro rata over the following 36 months, and each award has a 10‑year term.
Envoy Medical, Inc. received a Schedule 13G showing that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, and Waqas Khatri collectively report beneficial ownership of 2,457,963 shares of Class A common stock issuable upon exercise of warrants.
This position represents 7.87% of Envoy Medical’s common stock, calculated using 28,786,511 shares outstanding as of November 21, 2025, plus the warrant shares. The warrants are subject to a 9.99% beneficial ownership blocker, limiting how much of the company they can own at any time.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Envoy Medical. Voting and dispositive power over the 2,457,963 shares is reported as sole, with no shared power.